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Organ gene therapy represents a promising tool to correct diseases or improve graft
survival after transplantation. Polymorphic variation of the major histocompatibility
complex (MHC) antigens remains a major obstacle to long-term graft survival after
transplantation. Previously, we demonstrated that MHC-silenced cells are protected
against allogeneic immune responses. We also showed the feasibility to silence MHC
in the lung. Here, we aimed at the genetic engineering of the kidney toward permanent
silencing of MHC antigens in a rat model. We constructed a sub-normothermic ex vivo
perfusion system to deliver lentiviral vectors encoding shRNAs targeting β2-microglobulin
and the class II transactivator to the kidney. In addition, the vector contained the
sequence for a secreted nanoluciferase. After kidney transplantation (ktx), we detected
bioluminescence in the plasma and urine of recipients of an engineered kidney during
the 6 weeks of post-transplant monitoring, indicating a stable transgene expression.
Remarkably, transcript levels of β2-microglobulin and the class II transactivator were
decreased by 70% in kidneys expressing specific shRNAs. Kidney genetic modification
did not cause additional cell death compared to control kidneys after machine perfusion.
Nevertheless, cytokine secretion signatures were altered during perfusion with lentiviral
vectors as revealed by an increase in the secretion of IL-10, MIP-1α, MIP-2, IP-10, and
EGF and a decrease in the levels of IL-12, IL-17, MCP-1, and IFN-γ. Biodistribution
assays indicate that the localization of the vector was restricted to the graft. This study
shows the potential to generate immunologically invisible kidneys showing great promise
to support graft survival after transplantation and may contribute to reduce the burden
of immunosuppression.
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INTRODUCTION
Kidney transplantation remains the best treatment for end
stage renal diseases. However, the limited availability of organ
donors contribute to increased waiting times and high morbidity
and mortality on the waiting list. In Germany there are
currently 7,526 patients waiting on a kidney transplantation with
waiting times exceeding 10 years (DSO 2018) (1). Despite the
advances in histocompatibility and transplant immunology, the
success of kidney transplantation relies on the use of powerful
immunosuppressive agents that predispose the transplanted
patients to infections and malignancies (2, 3). Furthermore, still
a considerable number of patients develop graft failure (4–6).
The endothelium supports the renal vasculature and modulates
crucial mechanisms such as inflammation or thrombosis
contributing to the appropriate organ function. The impairment
of the endothelium or the mesenchymal transition of the
endothelial cells supporting fibrosis is a major cause for
acute or chronic allograft rejection. After transplantation, the
endothelium represents the frontier between the graft and
recipient, thereby being the most important immune checkpoint
(7–9). The discrepancies at the human leukocyte antigen (HLA)
loci between donors and recipients remain the major cause
for antibody medicated rejection (10). HLA expression on the
renal endothelium serves as a strong antigenic stimulus and is
simultaneously a main driver and a target of allogeneic immune
responses (11). Allograft loss after kidney transplantation is the
result of a tight and synergistic interplay between innate and
adaptive immune responses. This involves complex molecular
mechanisms based on T and B-cell activation, autophagy,
apoptosis, and inflammatory responses (12). Interaction of
HLA with T-cell receptor activates T-cell immune responses
that may directly target the allograft or induce the de novo
formation of donor specific antibodies (DSA). Remarkably,
approximately 63% of late kidney allograft dysfunction is a
consequence of antibody mediated rejection (ABMR) (13).
Donor specific antibodies (DSA) targeting HLA class I antigens
support inflammation and induce proliferation. Also, DSA
specific for HLA class II are often correlated to chronic allograft
rejection and may play an important role in necrosis of
endothelial cells (14, 15). Recently, ex vivo normothermic organ
perfusion has emerged as a promising biotechnological platform
to preserve and assess organ quality. An increasing number of
studies also suggests the potential of normothermic perfusion
to improve quality, resuscitate, and eventually repair the organ
(16). Organ gene therapy offers the possibility to modulate
intragraft gene signatures involved in renal pathologies or graft
survival. Nevertheless, in vivo non-viral or viral gene therapeutic
approaches have shown so far very low efficiencies and lack of
organ specificity. The use of lentiviral vectors allows a permanent
genetic modification of cells and tissues, but beside difficulties in
their large-scale production and purification so far representing
an obstacle to the genetic modification of large solid vascularized
organs, in vivo approaches lack specificity and are prone to off-
target effects (17). Therefore, viral vector-mediated transduction
during ex vivo organ perfusion may offer a promising approach
to generate stable genetically engineered organs (18). Previously,
we have demonstrated that silencing HLA expression reduce the
strength of allogeneic immune responses in vitro and in vivo (19–
22). Hence, in this study we aimed to induce a stable genetic
modification of the kidney during ex vivo organ perfusion. In
particular, in the interest of a precise regulation, we used RNA
interference to downregulate MHC class I and II transcript
in a rat kidney transplant model as a strategy to reduce the
immunogenicity of the allograft. This could offer many new
opportunities in transplant settings and contribute to gender and
diversity equality.
MATERIALS AND METHODS
Lentiviral Vector Constructs and Vector
Production
The pRRL.PPT.eFS.pre lentiviral vector plasmid encoding for
the sequence of a secreted form of luciferase from Oplophorus
gracilirostris (NanoLuc, NL) as a reporter gene was used
for cloning of an RNAi cassette (18). The cassette consisted
of U6 and H1 promoter sequences regulating expression of
shRNAs targeting rat beta2-microglobulin (β2m; shβ2m: 5′-
GGAAAGAAGATACCAAATA-3′) and rat class II transactivator
(CIITA; shCIITA: 5′-GGATATGGAAATGGATGAAGA-3′),
respectively. Thus, the ultimate construct was designed to silence
rat MHC I and rat MHC II genes expression. A vector containing
a sequence for a non-sense shRNA (shNS) was used as a control.
Lentiviral vector particles were produced in HEK293T cells
cultured in HYPERFlask Cell Culture Vessels (Corning, New
York, USA). The cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (FCS), 1%
glutamine and 2% penicillin-streptomycin until a confluence of
80–90% and then transfected. For the transfection, the shRNA-
encoding vector, as well as psPAX2 and pMD2.G plasmids were
mixed with polyethylenimine (Polysciences, Warrington, PA,
USA). Afterwards, this mix was applied onto the HEK293T cells
and incubated for 64 h. Then, the cell culture supernatants were
collected and centrifuged at 20,000 g, 16◦C for 3 h. Pellets of
viral vector particles were resuspended in Williams’ Media E
(WME) (Thermo Fisher Scientific, Waltham, MA, USA), divided
in 1ml aliquots and stored at −80◦C. Viral vector titration was
performed by p24 enzyme-linked immunosorbent assay (Cell
Biolabs, San Diego, CA, USA).
Transduction of Rat Kidneys With Lentiviral
Vectors During ex vivo Perfusion
Rat kidneys were perfused in a system designed to allow for the
constant roller-pump driven warm oxygenated perfusion (refer
to Supplementary Material for the perfusion system details).
Kidneys were perfused with WME media supplemented with
5% BSA, 0.007M creatinine and 30mM HEPES, as well as
500µg/ml Cefazoline, as previously described (23). After 10min
of cold storage upon retrieval, the organs were connected to the
perfusion system via a fragment of aorta and renal artery and
allowed to gradually rewarm to 26–29◦C, while being perfused
with gradually increasing pump speed for another 15min. At
this stage the flow rate typically reached 3–5 ml/min and the
Frontiers in Immunology | www.frontiersin.org 2 February 2020 | Volume 11 | Article 265
Yuzefovych et al. Kidney Genetic Engineering
pressure increased to 30–45 mmHg. Then, 0.8mg protamine
sulfate (Sigma–Aldrich, St. Louis, USA) and 1.5 × 1011 shβ2m-
and shCIITA-encoding or shNS-encoding vector particles were
injected into the system. Afterwards, the kidneys were perfused
at further increasing speed and temperature for about 20–
25min until the parameters were stabilized at 80–95 mmHg
and 31–32◦C, respectively. The entire perfusion time with the
viral vector was 2 h. Afterwards, the organs were perfused for
15min with WME-based perfusion solution containing EDTA-
treated blood, followed by another 10min of washing withWME-
based perfusion solution only. During the last two post-vector
perfusion stages, the kidneys were cooled down to 12–13◦C
and placed on ice for transportation to the operating room
for transplantation.
Experimental Animals
All animal experiments were conducted according to the
German Animal Welfare law and approved by the local
authority (Niedersächsisches Landesamt für Verbraucherschutz
und Lebensmittelsicherheit, Oldenburg, Germany). The animals
were bred in house and provided by Institute of Laboratory
Animals of Hannover Medical School, Hannover, Germany.
Left kidneys were retrieved from Lew.1W(WP)/HanZtm
rats and transplanted to Lew/NHanZtm in an orthotropic
allotransplantation setting (Supplementary Material contains
surgery details). Donors and recipients were 8–9 weeks oldmales.
A group of donor kidneys (n = 5) was transduced with the shNS
lentiviral vector as a control and another group was transduced
with the shβ2m and shCIITA-encoding vector (n = 7) during
the ex vivo perfusion prior to transplantation. Blood samples
were collected from the recipient rats before transplantation
and weekly thereafter by puncturing the retrobulbar venous
plexus with EDTA-coated microtubes (Sarstedt, Nuembrecht,
Germany). Plasmawas stored at−80◦Cuntil needed. In addition,
urine collection for 6 h during daytime in metabolic cages
was done prior and after ktx in weekly intervals. The urine
was stored at −80◦C until analysis. A follow up duration was
6 weeks. Afterwards, the recipients were sacrificed in deep
general anesthesia and several organs were retrieved. Brain, lung,
heart, liver, left native recipient kidney, transplanted kidney,
spleen, intestine and bone marrow tissue samples were collected,
frozen in liquid nitrogen or preserved in RNA later (Sigma,
St. Louis, MO, USA) and stored at −80◦C after sacrification.
The middle part of kidneys was fixed in 3.5–3.7% pH-neutral
buffered formaldehyde (Otto Fischar, Saarbruecken, Germany)
and embedded in paraffin for further histological analysis.
Detection of Secreted NanoLuc Luciferase
Reporter Gene Expression
Levels of secreted NanoLuc Luciferase reporter gene in plasma
and urine samples were measured with help of Nano-Glo
Luciferase Assay System (Promega, Madison, USA) according
to the manufacturer’s protocol. Briefly, 5 µl of plasma or urine
samples was diluted 1:10 with phosphate-buffered saline and
an equal volume of Nano-Glo Luciferase Assay Reagent was
added. The bioluminescence signal, generated as a result of
NanoLuc Luciferase interaction with its substrate furimazine,
was measured with a luminometer (Berthold Technologies, Zug,
Switzerland) after 3min of incubation.
Analysis of the Cytokine Secretion Profile
in the Course of Kidney Perfusion
Cytokine levels of rat IL-1α, MIP-1α, IL-6, EGF, IL-10, IL-
12p70, IFN-γ, IL-17, IL-18, MCP-1, IP-10, MIP-2, TNF-α, and
RANTES were measured in the perfusate samples using magnetic
multiplex bead technology and serummatrices (MerckMillipore,
Schwalbach, Germany). The perfusate samples collected at 5,
30min, 1 and 2 h time points after starting the perfusion were
centrifuged at 1,500 rpm for 5min at room temperature and
stored at −80◦C until the cytokines analysis was performed.
The samples were incubated with the beads according to the
manufacturer’s instructions. The beads were acquired using a
Luminex 100/200 device (Luminex Corp., Austin, TX, USA) and
the cytokine concentrations were calculated using the Xponent
software version 3.1 (Luminex Corp.).
Real-Time Polymerase Chain Reaction
Renal tissue samples stored in RNA later were used for
total RNA isolation with RNeasy Mini Kit (Qiagen, Hilden,
Germany) followed by reverse transcription using High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Foster
City, USA). Quantitative real-time polymerase chain reaction
(qRT-PCR) was utilized to characterize β2m (Rn00560865_m1;
Thermo Fisher Scientific, Waltham, MA, USA) and CIITA
(Rn01424725_ m1; Thermo Fisher Scientific) transcript levels
in amplification reaction with TaqMan Gene Expression Master
Mix (Thermo Fisher Scientific). GAPDH was chosen as
endogenous control for normalization (Rn01775763_g1; Thermo
Fisher Scientific). All samples were measured in triplicate with
StepOnePlus Real-Time PCR System and data processed with
StepOnePlus Software v2.3 (Applied Biosystems).
Lactate Dehydrogenase Activity in Kidney
Perfusion Solution
Perfusate samples collected at 5, 30, 60, 90, and 120min time
points in the course of kidney perfusion were centrifuged as
described before and stored at−80◦Cuntil lactate dehydrogenase
(LDH) activity was measured with Cytotoxicity Detection
Kit (LDH) (Roche, Basel, Switzerland) according to the
manufacturer’s instructions. Optical density units of the
colorimetric reaction of iodonitrotetrazolium conversion into a
red colored formazan were used for comparing LDH release at
different time points during kidney perfusions.
Histology
Formaldehyde-fixed renal tissue samples were embedded in
paraffin for cutting. Five micrometer sections were prepared
and stained with haematoxylin and eosin (H&E). Pathological
evaluation of all relevant renal structures including glomeruli,
tubuli, blood vessels, and interstitial tissue was performed.
A special attention was given to characteristic features of
acute tubular injury (ATI) such as tubular swelling, edema
and distension, brush border loss, tubular epithelial lucency,
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flattening, pyknosis, nuclei loss, luminal debris, and tubular
necrosis (epithelial cell death).
Lentiviral Vector Biodistribution Assay
Six weeks after transplantation, the animals were sacrificed
and tissue samples of brain, lung, heart, liver, native
kidney, transplanted kidney, spleen, intestine, and bone
marrow were collected and frozen in liquid nitrogen as
described before. These samples were used for genomic
DNA (gDNA) isolation with NucleoSpin Tissue Kit
(Macherey-Nagel, Düren, Germany). Isolated gDNA was
used in a polymerase chain reaction (PCR) to amplify a
296 bp fragment of the genome-integrated lentiviral vector
sequence. BIO-X-ACT Short Mix (Bioline, London, UK)
and the primers 5′-AATTCGGTTAAGGCCAGGGG-3′; 5′-
GCTGTGCGGTGGTCTTACTT-3′ were used for amplification.
The PCR product was then separated by electrophoresis
next to Quick-Load Purple 100 bp DNA Ladder (New
England Biolabs, Ipswich, USA) on a 2% agarose gel with
GelStar Nucleic Acid Gel Stain (Lonza, Basel, Switzerland).
Images were captured with ChemiDoc MP Imaging System
(BioRad, Hercules, CA, USA) and the band intensities were
calculated by densitometric analysis using the BioRad Image
Lab 6.0.1 software.
Statistical Analyses
Data are presented as mean ± standard deviations (SD).
For comparison of two groups the Student’s t-test was used.
Comparison of multiple groups with two independent variables
was performed by two-way-ANOVA. p < 0.05 were considered
significant. Statistical analyses were performed using GraphPad
Prism v5.0 (GraphPad Software Inc., San Diego, CA, USA).
RESULTS
Lentiviral Vector Mediated Transgene
Delivery Into Rat Kidneys During ex vivo
Sub-normothermic Perfusion and
Subsequent Transplantation
Ex vivo kidney perfusion (EVKP) creates a unique opportunity
to genetically engineer the organ. Here, we combine EVKP
with lentiviral transduction strategies to genetically modify a
rat kidney. For this purpose, we constructed a perfusion system
(Figure 1A) to accommodate a rat kidney and allow ex vivo
perfusion with warm oxygenatedWME-based perfusion solution
(Figure 1B) and monitoring of major perfusion parameters. In
this miniature EVKP system, flow rates of 9–12 ml/min and
pressure of 80–95 mmHg under sub-normothermic conditions
(32◦C) were achieved. Saturation of O2 (sO2) in the perfusion
solution of 65–70% was achieved using a silicone tubing
oxygenator submerged in a Büchner flask supplied with carbogen
(Supplementary Figure 1). In addition, the perfusion circuit
enabled the injection, transport and delivery of lentiviral particles
into the rat kidney. Transduced kidneys were subsequently
transplanted into allogenic recipients. Experimental design of the
study is depicted in Figure 1C and summarized as follows: (1)
kidney retrieval from the donor; (2) genetic modification of the
kidney with the lentiviral vector during 2 h of EVKP; (3) kidney
transplantation (ktx) into the recipient; (4) six weeks monitoring
of the transgene expression in the recipient after ktx.
Detection of the Transgene Expression
Post-transplantation
NanoLuc Luciferase Reporter Gene Expression
The lentiviral vector constructs encoding for shNS or shβ2m and
shCIITA sequences used in this study also contained the sequence
FIGURE 1 | Rat kidney perfusion system for ex vivo perfusion and organ genetic engineering. The photographs show the EVKP system (A) and the rat kidney
connected to the perfusion system via cannulation of the renal artery (B). Schematic representation of the experimental design of the study, including kidney
explantation, genetic modification with lentiviral vectors and transplantation (C). Retrieved kidney was placed in the organ container and the renal artery was
cannulated and connected to the system. Perfusate flowed from the renal vein into a reservoir for recirculation. Vector particles were injected into the reservoir. A
peristaltic pump induced the circulation of the perfusate from the reservoir toward the kidney passing by an oxygenator and glass heat-exchanger. The oxygenated
and warmed perfusate entered the kidney via renal arterial cannula.
Frontiers in Immunology | www.frontiersin.org 4 February 2020 | Volume 11 | Article 265
Yuzefovych et al. Kidney Genetic Engineering
for secreted NanoLuc Luciferase (NL) as a reporter gene. Kidney
transduction was measured by evaluation of bioluminescence
activity in the body fluids of animals transplanted with genetically
engineered kidneys. In comparison to levels of bioluminescence
detected in the pre-transplant plasma samples, all animals
transplanted with a graft perfused with lentiviral vectors
encoding for NL showed an increase in relative luminescence
units (RLU) already 1 week post-transplantation 2.67 × 104 to
1.24 × 106 RLU above the pre-transplantation baseline levels.
Bioluminescence in plasma samples was detectable during the
entire monitoring period and showed 9.64 × 103 to 3.76 × 105
RLU at week 6 (Figure 2A). In addition, weekly urine samples
were collected from 8 transplanted rats (3 shNS and 5 shβ2m
and shCIITA) (Figure 2B). In urine, bioluminescence increased
1 week post-transplantation, similar to plasma, but reached
their peak at week 3 showing 2.06 × 106 RLU above the pre-
transplantation baseline. Although, the bioluminescence activity
was detectable in urine samples during the entire monitoring
time the RLU decreased toward 6 weeks and varied between 1.35
× 103 and 1.56 × 106 (Figure 2B) at the end of the observation
time.Means of NL bioluminescence detected in urine and plasma
of animals transplanted with shβ2m and shCIITA or shNS renal
grafts are shown in Figures 2C,D.
Gene Expression Regulation by shβ2m and
shCIITA-Encoding Lentiviral Vector
Increase in NL bioluminescence levels in plasma and urine
are indicators of a successful transduction of the renal tissue
during EVKP. Hence, MHC class I and II-related transcript levels
were evaluated after 6 weeks post-transplantation with shNS-
or shβ2m and shCIITA-expressing kidneys. A downregulation
of up to 71% in β2-microglobulin levels was detectable in the
kidneys engineered for the expression of shβ2m in comparison
to shNS-expressing grafts (Figure 3A). Similarly, rat CIITA
transcript levels were decreased by 70% in the kidneys perfused
FIGURE 2 | Genetic modification of the kidney during ex vivo perfusion. Bioluminescence detected in plasma of the rats transplanted with shβ2m and shCIITA or
shNS genetically engineered kidneys. The graphs depict relative luminescence units (RLU) of the secreted NanoLuc Luciferase (NL) reporter gene activity before
transplantation and in the course of 6 weeks post-transplantation monitoring (A). Urine bioluminescence levels of the animals transplanted with shβ2m and shCIITA or
shNS genetically engineered kidneys. Pre-transplantation NL reporter gene activity levels and NL activity values during 6 weeks after the surgery are shown (B). Mean
of RLU detected in plasma of the rats transplanted with shβ2m and shCIITA (n = 7) or shNS-expressing (n = 5) kidneys (Mean ± SD) (C). Mean of RLU measured in
urine of animals transplanted with shβ2m and shCIITA (n = 5) or shNS-expressing (n = 3) kidneys (Mean ± SD) (D). Pre ktx—pre-transplantation. Statistical analysis
was performed by two-way ANOVA. No statistical significance was observed between shNS and the MHC-silence groups.
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FIGURE 3 | Silencing of β2m and CIITA transcript levels. Relative quantification
(RQ) of the β2m gene expression in the kidneys genetically modified with the
lentiviral vectors encoding shβ2m and shCIITA (n = 7) or shNS (n = 5) detected
by qRT-PCR (Mean ± SD) (A). RQ values of the CIITA gene transcripts
detected by qRT-PCR in shβ2m and shCIITA (n = 7) or shNS-transduced (n =
5) kidneys (Mean ± SD) (B). Levels of β2m and CIITA gene expression were
normalized to GAPDH as housekeeping gene. *p < 0.05 (t-test).
with shCIITA-encoding vector particles in comparison to shNS-
treated control kidneys (Figure 3B). These data indicate that
the lentiviral vector harboring shβ2m and shCIITA and applied
during EVKP has the potential to simultaneously downregulate
the expression of MHC class I and II-related transcript levels.
Assessment of the Kidney Tissue Quality
and Integrity in the Course of
Sub-Normothermic ex vivo Perfusion With
Lentiviral Vectors
Lactate Dehydrogenase Activity and Histological
Analysis
Levels of lactate dehydrogenase (LDH) have been used as a
marker for tissue integrity (24). In order to estimate the level
of potential tissue damage induced by the presence of lentiviral
vector particles in the perfusion solution during EVKP, we
selected LDH as a tissue damagemarker andmeasured its activity
in kidney perfusates. Levels of LDH activity increased with
time during EVKP. But importantly, no significant differences
in the perfusate LDH levels were observed between kidneys
perfused with lentiviral particles and control kidneys perfused
only with medium at 5, 30, 60, 90, and 120min time point
(Figure 4). Histopathological findings of the renal tissue samples
exposed to the lentiviral vector encoding for shβ2m and shCIITA
during EVKP and control kidney samples perfused only with
medium were comparable. Both showed potentially reversible
mild to moderate acute tubular injury with overall intact renal
FIGURE 4 | Genetic engineering of the kidney does not cause cell damage.
Levels of lactate dehydrogenase (LDH) activity in perfusion solution of the
control kidneys (n = 3) vs. kidneys subjected to lentiviral vector transduction (n
= 4) were measured at the beginning (5min) and every 30min during EVKP
(Mean ± SD). No significant difference in LDH activity was observed between
control and lentiviral vector groups as calculated by two-way ANOVA.
morphology. No vector-specific damage in the kidneys perfused
with the lentiviral vector was detected (Figure 5). These data
suggest that application of lentiviral vectors for ex vivo kidney
genetic engineering under conditions of sub-normothermic
perfusion does not cause additional tissue damage in comparison
to kidneys perfused without vector.
Cytokines Secretion Profile
Cytokines are important immunomodulatory agents during
immune responses after transplantation (25). Therefore, we
have characterized potential alterations in the kidney cytokine
secretion profile during EVKP in presence or absence of lentiviral
vector particles. In comparison to kidneys perfused without
vectors, no IL-17 or IFN-γ and lower concentrations of IL-12
and MCP-1 were detectable in kidneys perfused with vector
particles during the entire perfusion time. Levels of IL-6 were
lower during early perfusion time with lentiviral vectors, but
increased at later time point (2 h) to similar concentrations as
detected in the kidneys perfused without vectors. In contrast,
the secreted levels of IL-10, MIP-1α, MIP-2, IP-10, TNF-α, and
EGFwere significantly increased in perfusates of kidneys exposed
to the lentiviral particles, but only at later time point (2 h). No
differences were observed in the secretion patterns of RANTES
in kidneys perfused with or without lentiviral vectors. IL-1α
and IL-18 were not detected in any of the samples at any
time point (Figure 6). These data suggest that perfusion with
lentiviral vectors induce an alteration in the pattern of secretion
of cytokines.
Biodistribution Assay
Ex vivo organ perfusion permits the precise genetic engineering
of the target organ, strongly reducing the risk for undesired
off-target effects or adverse reactions due to not modifying the
cells or other organs. Hence, after transplantation of genetic
engineered kidneys, we have assessed different organs for the
presence of the lentiviral vector. The vector could not be found
in any other organ and was exclusively restricted to the modified
renal graft (Figure 7).
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FIGURE 5 | Representative images of perfused kidneys, H&E stain. Perfused control kidneys (A,C) or kidneys perfused with lentiviral vector (B,D) showed mild to
moderate acute tubular injury characterized by tubular vacuolization (arrows, v, vessel). Overall renal morphology was intact in both groups. Images represent
individual kidneys from 4 different rats (bar: 100µm).
DISCUSSION
In this study, we have demonstrated that the kidney can be
genetically engineered in a permanent manner toward reduction
of its immunogenicity.
Organ Gene Therapy
Recently, gene therapeutic approaches have demonstrated to
be successful in the treatment of several diseases such as
inherited retinal dystrophies, cancer, hemoglobinopathies and
neuromuscular diseases using non-viral or viral-based vector
technologies (26–30). Furthermore, several pre-clinical studies
show significant progresses in the development of gene
therapeutic strategies at organs such as the lung and the liver (31,
32). Selection of the method to deliver of the therapeutic vectors
remains an essential and crucial hallmark; on the one hand
to achieve organ specificity and high transduction efficiencies
and on the other hand to ensure maintenance of organ quality
during the genetic engineering process. Despite many efforts, in
vivo delivery of gene therapeutic vectors has been proven to be
inefficient and unspecific (17).
Ex vivo Organ Perfusion in Organ
Engineering
Ex vivo normothermic perfusion has been extensively studied
during the past decade and it has allowed to monitor function
and circulation in marginal organs, such as in case of donation
after circulatory death or from extended criteria donors, in
kidney, lung, heart and liver transplantation studies and also
to deliver certain therapeutic strategies (33–35). During ex vivo
normothermic perfusion the donated organ undergoes machine
perfusion with warm and oxygenated blood or preservation
solution prior to transplantation. The feasibility of ex vivo
normothermic perfusion for long periods such as 24 h was
previously demonstrated (36). The prolonged warm perfusion
time with maintenance of functionality creates a window
of opportunity for various therapeutic interventions. Among
those, genetic organ engineering is one of the most promising
opportunities to correct monogenetic diseases or support
allograft survival after transplantation.
Immuno-Engineering of the Kidney
Recently, we have shown the possibility to engineer the lung
endothelium by lentiviral vectors during ex vivo normothermic
perfusion in a porcine model (18). In a porcine heart study it has
been reported that the intravascular delivery of adenoviral (Ad)
vectors encoding the luciferase gene led to widespread transgene
expression in the allograft (37). The intrabronchial route was
also exploited in porcine lungs for genetic modification with
human IL-10 encoding Ad vector during ex vivo normothermic
perfusion (38). Furthermore, it has been reported that glomeruli
had been extensively transduced with an Ad vector encoding
for β-galactosidase after normothermic EVKP in a porcine
model (39). These studies indicate that EVKP creates favorable
conditions for genetic organ engineering. In contrast to Ad
or Ad-associated vectors, lentiviral vectors enable a permanent
transgene expression which might be essential to support
long-term graft survival. Human Leukocyte Antigen (HLA)
mismatches between donor and recipients remain a major
obstacle in allogeneic transplantation. However, ∼38% of
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FIGURE 6 | Cytokine secretion signatures during ex vivo perfusion and kidney genetic engineering. Cytokine secretion profiles detected in the perfusion solution of the
control kidneys (n = 4) and kidneys exposed to the shβ2m and shCIITA (n = 3) or shNS-encoding (n = 3) lentiviral vectors during EVKP (Mean ± SD). ***p < 0.001,
**p < 0.01 (shβ2m and shCIITA or shNS vs. control, two-way ANOVA).
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FIGURE 7 | Biodistribution analysis of the lentiviral vector used for genetic modification of the kidneys during ex vivo perfusion. The localization of the vector is
restricted to the engineered graft. Representative picture of the lentiviral vector biodistribution assay in rat organs and tissues 6 weeks after transplantation with ex vivo
genetically engineered kidneys. Densitometric analysis of the bands was performed using the BioRad Image Lab 6.0.1 software. Tx, genetically engineered
transplanted kidney; NTC, no template control.
kidney graft failure is expected to be triggered by non-HLA-
dependent factors. In fact, evidences for the relevance of non-
HLA antibodies in leading to kidney transplant dysfunction
is increasing. Tissue injury caused by ischemia-reperfusion
or vascular injury may favor the upregulation of cryptic
autoantigens on the graft endothelial cells such as the angiotensin
II type 1 receptor and serve as a target for autoantibodies
after transplantation (40, 41). Recently, RNAi has gained plenty
of attention in organ transplantation in particular to prevent
ischemia reperfusion injury (IRI) by silencing the expression
of different genes such as Caspase 3, IKKβ, Fas or RelB. Most
of these studies used chemically modified siRNAs or siRNA
sequences encoded by plasmid DNA administrated via arterial
or venous infusion or injection to prevent IRI. Gene silencing
effects using stabilized siRNAs were detectable by periods of
2 to 3 weeks (42–46). In this study, we have selected RNAi
as technology to silence MHC class I and II expression and
lentiviral vectors to ensure a prolonged expression of the
shRNAs. It is well-known that the abrogation of MHC class I
expression triggers NK cell cytotoxicity. In previous studies, we
have demonstrated that the residual expression of MHC class
I molecules is required to prevent NK cell cytotoxicity (22).
Thus, we have selected RNAi as the gene regulatory strategy to
downregulate MHC expression and not gene editing tools such
as CRISPR/Cas9 or TALENs which would generate a complete
MHC knockout. In addition, gene regulatory strategies also
enable the re-expression of the targeted gene in case of interest
by using Tet-ON/OFF promoters. This may be beneficial in
case of infections or tumor development. Here, we showed
the lentiviral-mediated transduction of the kidney during ex
vivo perfusion and the sustained transgene expression after
ktx as demonstrated by the levels of luminescence in plasma
and urine samples of the animals 6 weeks after transplantation
(Figure 2, Supplementary Figure 2). This stable transduction
of the kidney grafts is in line with our results in the porcine
lung model showing the lentiviral delivery of shRNAs to induce
a specific downregulation of MHC class I and MHC class II
transcripts (18). We have detected an increase in LDH during
perfusion time, however this tendency has also been previously
observed in different studies focused in the ex vivo recirculating
perfusion of organs such as the kidney, liver and lung. This
was mainly explained by periods of warm ischemia prior
perfusion and by the effect of using pumps and cardiopulmonary
bypass during perfusion (18, 47–49). Importantly, we showed
that the transduction of the kidney with lentiviral vectors did
not cause additional tissue injury or cell death as detected
by the LDH levels in the kidney perfusate and renal tissue
histological analysis. In order to minimize the risks for cell
damage during perfusion, the perfusion solution was oxygenated
in our system. Previous studies have indicated the benefits of
oxygenating the perfusion solution already during hypothermic
perfusion by reducing oxidative stress and supporting the energy
status in presence of low metabolic rates (50, 51). During
sub-normothermic to normothermic perfusion the increased
metabolism demands an appropriate oxygen supply, but recent
studies indicate that normothermic perfusion with reduced
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perfusate oxygenation for a limited period of time may also be
possible without severely compromising renal function or tissue
integrity (52).
Cytokines play essential roles in the maintenance of tissue
homeostasis and host defense. However, dysregulation of typical
cytokine release patterns may trigger detrimental immune
cascades after transplantation (25). Previous studies reported
that the procedure of organ ex vivo perfusion itself elicits
an inflammatory reaction with increasing cytokine levels after
harvest and placement of organs on the pump-driven perfusion
system (53). In this study, we compared cytokine signatures
between rat kidneys perfused without and with lentiviral
vectors. An increase in the secretion of MIP-1α, MIP-2, IP-
10, IL-10, and EGF was detected in the perfusate of organs
exposed to lentiviral vectors during perfusion in this model.
In contrast, the secretion of cytokines IL-12p70, IL-17, MCP-
1, and IFN-γ was lower in genetically engineered organs. The
impact of this change in the cytokine secretion pattern in the
transplantation outcome needs to be investigated in detail in
future experiments. Currently, different approaches to prevent
the release of pro-inflammatory cytokines by ex vivo perfused
organs based on the use of membranes or small molecules are
being developed to avoid tissue impairment during perfusion
or the activation and polarization of immune responses after
transplantation (54, 55).
Safety
Lentiviral vectors are powerful tools for genetic engineering
and their use in clinical trials is rising. Nevertheless, the use
of lentiviral vectors might be associated with safety concerns
such as an increased risk for tumorigenesis (56). In contrast
to the in vivo application of lentiviral vectors, ex vivo organ
perfusion allows for the selective genetic modification of the
target organ thereby reducing the possibility for off-target and
systemic adverse effects. In the transplantation setting an ex
vivo period of the allograft between transplant procurement and
recipient transplantation is inevitable. This inevitable ex vivo
period of the graft provides a unique opportunity for an ex vivo
transplant engineering taking advantage of not having to accept
systemic off-target effects. In our study, we showed that after
transplantation of transduced kidneys the integrated vector DNA
was exclusively restricted to the genetically engineered organs.
Hence, delivery of the lentiviral vector during ex vivo perfusion
not only permits the efficient transduction of the organ and stable
transgene expression, but simultaneously supports the safety of
this procedure.
CONCLUSIONS
In this study, we have demonstrated the feasibility to engineer
the kidney during ex vivo perfusion over prolonged time periods.
Furthermore, levels of MHC class I and II transcripts were also
stably downregulated. In future studies, the benefit of invisible
of MHC-silenced allografts will need to be investigated toward
improvement of allograft survival, function, and reduction of
development of donor specific antibodies. Long term goals would
be to reduce the amount of immunosuppression and ideally to
induce tolerance toward the allograft.
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